Startup profile · funding coverage
Breye Therapeutics funding, valuation and investors
Clinical-stage ophthalmology biotech that raised €67.5 million in an oversubscribed Series A.
Keep track of Breye Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
€67.5M · September 29, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Hørsholm, Denmark
Investors in latest funding
Lead: Mission BioCapital , Novo Holdings
Other: Sound Bioventures
Overview
Breye Therapeutics develops oral therapies for retinal diseases, including danegaptide for non-proliferative diabetic retinopathy. On September 29, 2026 the company announced an oversubscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings.
Why Breye Therapeutics is interesting
Large European Series A funding oral therapies for retinal disease, with primary-source confirmation.
Key facts
- Sep 29, 2026: €67.5M Series A
- Funding supports Phase II development of danegaptide
Funding history (newest first)
Series A
2026-09-29 €67.5M- Mission BioCapital (lead)
- Novo Holdings (lead)
- Sound Bioventures (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.